Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An acute and continuation phase study of the comparative efficacy of venlafaxine ER (Effexor XR) and fluoxetine (Prozac) in achieving and sustaining remission (wellness) in patients with recurrent unipolar major depression; followed by a long term randomized, placebo-controlled maintenance treatment study in patients treated initially with venlafaxine ER

Trial Profile

An acute and continuation phase study of the comparative efficacy of venlafaxine ER (Effexor XR) and fluoxetine (Prozac) in achieving and sustaining remission (wellness) in patients with recurrent unipolar major depression; followed by a long term randomized, placebo-controlled maintenance treatment study in patients treated initially with venlafaxine ER

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venlafaxine (Primary) ; Fluoxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Most Recent Events

    • 01 Sep 2015 Results of post hoc analysis presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 18 Aug 2009 Actual initiation date (1 Aug 2000) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Actual end date (1 Oct 2005) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top